JP2024507938A5 - - Google Patents
Info
- Publication number
- JP2024507938A5 JP2024507938A5 JP2023551767A JP2023551767A JP2024507938A5 JP 2024507938 A5 JP2024507938 A5 JP 2024507938A5 JP 2023551767 A JP2023551767 A JP 2023551767A JP 2023551767 A JP2023551767 A JP 2023551767A JP 2024507938 A5 JP2024507938 A5 JP 2024507938A5
- Authority
- JP
- Japan
- Prior art keywords
- agent according
- formula
- pharmaceutically acceptable
- compound
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21382163.0 | 2021-02-25 | ||
| EP21382163 | 2021-02-25 | ||
| US202163232866P | 2021-08-13 | 2021-08-13 | |
| US63/232,866 | 2021-08-13 | ||
| US202263297098P | 2022-01-06 | 2022-01-06 | |
| US63/297,098 | 2022-01-06 | ||
| PCT/US2022/017678 WO2022182857A1 (en) | 2021-02-25 | 2022-02-24 | Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024507938A JP2024507938A (ja) | 2024-02-21 |
| JP2024507938A5 true JP2024507938A5 (https=) | 2025-03-04 |
Family
ID=80786345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023551767A Pending JP2024507938A (ja) | 2021-02-25 | 2022-02-24 | 骨髄線維症の治療としてのｂｅｔ阻害剤の使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12357621B2 (https=) |
| EP (1) | EP4297750A1 (https=) |
| JP (1) | JP2024507938A (https=) |
| KR (1) | KR20230148208A (https=) |
| AU (1) | AU2022227673A1 (https=) |
| CA (1) | CA3206708A1 (https=) |
| CL (1) | CL2023002497A1 (https=) |
| IL (1) | IL304697A (https=) |
| MX (1) | MX2023009858A (https=) |
| TW (1) | TW202302095A (https=) |
| WO (1) | WO2022182857A1 (https=) |
| ZA (1) | ZA202307538B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022261204A1 (en) | 2021-06-08 | 2022-12-15 | The Regents Of The University Of California | Anticancer compounds |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5191391B2 (ja) | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| KR20150036210A (ko) | 2007-06-13 | 2015-04-07 | 인사이트 코포레이션 | 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염 |
| AU2010363329A1 (en) | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| KR102457145B1 (ko) * | 2013-12-24 | 2022-10-19 | 브리스톨-마이어스 스큅 컴퍼니 | 항암제로서의 트리시클릭 화합물 |
| US9458156B2 (en) | 2014-12-23 | 2016-10-04 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| EP3355922A2 (en) * | 2015-10-02 | 2018-08-08 | Dana Farber Cancer Institute, Inc. | Combination therapy of bromodomain inhibitors and checkpoint blockade |
| US12391676B2 (en) * | 2018-09-07 | 2025-08-19 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | BRD4-JAK2 inhibitors |
| BR112021005518A2 (pt) | 2018-09-25 | 2021-06-29 | Impact Biomedicines, Inc. | métodos para tratar distúrbios mieloproliferativos |
| FI3908281T3 (fi) * | 2019-01-09 | 2024-10-01 | Celgene Corp | Antiproliferatiivisia yhdisteitä ja toisia aktiivisia aineita käytettäväksi multippelin myelooman hoidossa |
| US12559463B2 (en) | 2019-02-12 | 2026-02-24 | Impact Biomedicines Inc. | Crystalline forms of a JAK2 inhibitor |
| PT4161528T (pt) * | 2020-06-03 | 2026-01-23 | Incyte Corp | Combinação de ruxolitinib com incb057643 para utilização no tratamento de neoplasias mieloproliferativas |
-
2022
- 2022-02-24 MX MX2023009858A patent/MX2023009858A/es unknown
- 2022-02-24 KR KR1020237031973A patent/KR20230148208A/ko active Pending
- 2022-02-24 AU AU2022227673A patent/AU2022227673A1/en active Pending
- 2022-02-24 EP EP22708261.7A patent/EP4297750A1/en active Pending
- 2022-02-24 CA CA3206708A patent/CA3206708A1/en active Pending
- 2022-02-24 JP JP2023551767A patent/JP2024507938A/ja active Pending
- 2022-02-24 WO PCT/US2022/017678 patent/WO2022182857A1/en not_active Ceased
- 2022-02-25 US US17/680,569 patent/US12357621B2/en active Active
- 2022-02-25 TW TW111107087A patent/TW202302095A/zh unknown
-
2023
- 2023-07-24 IL IL304697A patent/IL304697A/en unknown
- 2023-07-28 ZA ZA2023/07538A patent/ZA202307538B/en unknown
- 2023-08-23 CL CL2023002497A patent/CL2023002497A1/es unknown
-
2025
- 2025-06-12 US US19/236,392 patent/US20250367174A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024507938A5 (https=) | ||
| JP2024133475A5 (https=) | ||
| JP2024133474A5 (https=) | ||
| JP2022009090A5 (https=) | ||
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| JP2022545005A5 (https=) | ||
| JP2019503365A5 (https=) | ||
| JP2011503063A5 (https=) | ||
| WO2020102804A3 (en) | Pharmaceutical combination for treatment of cancer | |
| JP2014526503A5 (https=) | ||
| JP2018526376A5 (https=) | ||
| JP2006523216A5 (https=) | ||
| JP2021509680A5 (https=) | ||
| EA037152B1 (ru) | Способ лечения рака | |
| JP2022540421A5 (https=) | ||
| JP2020523354A5 (https=) | ||
| JP2024516795A5 (https=) | ||
| JP2014512355A5 (https=) | ||
| JP2019508476A5 (https=) | ||
| JP2023548190A5 (https=) | ||
| CN103533940A (zh) | 治疗晚期实体瘤的方法 | |
| AU2017205749A1 (en) | Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof | |
| JP2015517523A5 (https=) | ||
| JP2016502981A5 (https=) | ||
| JP2018516936A5 (https=) |